Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 872 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared... August 26, 2024 European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025 March 20, 2025 Having Cancer as a Young Adult Put Me on a Path... May 25, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel August 26, 2025 Load more HOT NEWS Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients... Studying Genes and Proteins Together Sheds New Light on Colon Cancer ESMO welcomes the adoption of European Parliament Report on Europe’s Beating... Utility of Genomic Profiling Use for Targeted Therapy in a Phase...
